SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore

GSK registers 5% revenue growth in Q2 FY24

General Medicine grows 5% and Vaccines 10% led by Shingrix

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal

The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region

Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023

Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023

Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India

The drug will be marketed by Sun Pharma under the brand name RYTSTAT

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan